JP3643107B2 - （ｓ）−４−アミノ−５−クロロ−２−メトキシ−ｎ−［１−［１−（２−テトラヒドロフリルカルボニル）−４−ピペリジニルメチル］−４−ピペリジニル］ベンズアミド、その製造方法、それを含有する医薬組成物及び該化合物の中間体 - Google Patents

（ｓ）−４−アミノ−５−クロロ−２−メトキシ−ｎ−［１−［１−（２−テトラヒドロフリルカルボニル）−４−ピペリジニルメチル］−４−ピペリジニル］ベンズアミド、その製造方法、それを含有する医薬組成物及び該化合物の中間体 Download PDF

Info

Publication number
JP3643107B2
JP3643107B2 JP2003137413A JP2003137413A JP3643107B2 JP 3643107 B2 JP3643107 B2 JP 3643107B2 JP 2003137413 A JP2003137413 A JP 2003137413A JP 2003137413 A JP2003137413 A JP 2003137413A JP 3643107 B2 JP3643107 B2 JP 3643107B2
Authority
JP
Japan
Prior art keywords
compound
piperidinylmethyl
amino
chloro
tetrahydrofurylcarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003137413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004043453A (ja
JP2004043453A5 (enExample
Inventor
志朗 賀登
宏 山崎
美視 広川
陽子 菅
直之 吉田
一夫 森影
幸子 森影
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Dainippon Pharmaceutical Co Ltd
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co Ltd, Sumitomo Dainippon Pharma Co Ltd filed Critical Dainippon Pharmaceutical Co Ltd
Priority to JP2003137413A priority Critical patent/JP3643107B2/ja
Publication of JP2004043453A publication Critical patent/JP2004043453A/ja
Application granted granted Critical
Publication of JP3643107B2 publication Critical patent/JP3643107B2/ja
Publication of JP2004043453A5 publication Critical patent/JP2004043453A5/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2003137413A 2002-05-16 2003-05-15 （ｓ）−４−アミノ−５−クロロ−２−メトキシ−ｎ−［１−［１−（２−テトラヒドロフリルカルボニル）−４−ピペリジニルメチル］−４−ピペリジニル］ベンズアミド、その製造方法、それを含有する医薬組成物及び該化合物の中間体 Expired - Fee Related JP3643107B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003137413A JP3643107B2 (ja) 2002-05-16 2003-05-15 （ｓ）−４−アミノ−５−クロロ−２−メトキシ−ｎ−［１−［１−（２−テトラヒドロフリルカルボニル）−４−ピペリジニルメチル］−４−ピペリジニル］ベンズアミド、その製造方法、それを含有する医薬組成物及び該化合物の中間体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002141262 2002-05-16
JP2003137413A JP3643107B2 (ja) 2002-05-16 2003-05-15 （ｓ）−４−アミノ−５−クロロ−２−メトキシ−ｎ−［１−［１−（２−テトラヒドロフリルカルボニル）−４−ピペリジニルメチル］−４−ピペリジニル］ベンズアミド、その製造方法、それを含有する医薬組成物及び該化合物の中間体

Publications (3)

Publication Number Publication Date
JP2004043453A JP2004043453A (ja) 2004-02-12
JP3643107B2 true JP3643107B2 (ja) 2005-04-27
JP2004043453A5 JP2004043453A5 (enExample) 2005-06-16

Family

ID=29267809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003137413A Expired - Fee Related JP3643107B2 (ja) 2002-05-16 2003-05-15 （ｓ）−４−アミノ−５−クロロ−２−メトキシ−ｎ−［１−［１−（２−テトラヒドロフリルカルボニル）−４−ピペリジニルメチル］−４−ピペリジニル］ベンズアミド、その製造方法、それを含有する医薬組成物及び該化合物の中間体

Country Status (26)

Country Link
US (1) US6696468B2 (enExample)
EP (1) EP1362857B1 (enExample)
JP (1) JP3643107B2 (enExample)
KR (1) KR20040107520A (enExample)
CN (1) CN1653063A (enExample)
AR (1) AR040021A1 (enExample)
AT (1) ATE273304T1 (enExample)
AU (1) AU2003230245A1 (enExample)
BR (1) BR0309933A (enExample)
CA (1) CA2483368A1 (enExample)
CZ (1) CZ20041084A3 (enExample)
DE (1) DE60300021T2 (enExample)
DK (1) DK1362857T3 (enExample)
ES (1) ES2227500T3 (enExample)
HU (1) HUP0501016A2 (enExample)
IL (1) IL165012A0 (enExample)
MX (1) MXPA04011332A (enExample)
NO (1) NO20045469L (enExample)
PL (1) PL372724A1 (enExample)
PT (1) PT1362857E (enExample)
RU (1) RU2004136853A (enExample)
SK (1) SK50192004A3 (enExample)
TR (1) TR200403020T2 (enExample)
TW (1) TW200400186A (enExample)
WO (1) WO2003097638A1 (enExample)
ZA (1) ZA200409053B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
DE602005016446D1 (de) * 2004-11-05 2009-10-15 Theravance Inc 5-HT4-Rezeptoragonistenverbindungen
ES2327142T3 (es) * 2004-11-05 2009-10-26 Theravance, Inc. Compuestos de quinolinona-carboxamida.
ES2347265T3 (es) * 2004-12-22 2010-10-27 Theravance, Inc. Compuestos de indazol-carboxamida.
EP1871772B1 (en) * 2005-03-02 2014-09-10 Theravance, Inc. Quinolinone compounds as 5-ht4 receptor agonists
US7256294B2 (en) * 2005-05-25 2007-08-14 Theravance, Inc. Crystalline form of a benzimidazole-carboxamide medicinal compound
MY147756A (en) 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
TW200722419A (en) * 2005-05-27 2007-06-16 Astrazeneca Ab Chemical compounds
US20080200505A1 (en) * 2005-05-27 2008-08-21 Astrazeneca Ab Piperidines for the Treatment of Chemokine Mediated Diseases
JP2009501793A (ja) 2005-07-21 2009-01-22 アストラゼネカ・アクチエボラーグ 新規ピペリジン誘導体
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
TWI423967B (zh) * 2008-02-21 2014-01-21 Dainippon Sumitomo Pharma Co 醯胺衍生物及含有其之醫藥組合物
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
EA201491990A1 (ru) 2012-05-03 2015-02-27 Новартис Аг L-малатная соль 2,7-диазаспиро[4.5]дец-7-иловых производных и их кристаллические формы в качестве агонистов грелиновых рецепторов

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH111472A (ja) 1996-04-30 1999-01-06 Dainippon Pharmaceut Co Ltd ベンズアミド誘導体及びそれを含有する医薬組成物
DE69922186T2 (de) * 1998-04-28 2005-05-04 Dainippon Pharmaceutical Co., Ltd. 1-(1-subst.-4-piperidinyl)methyl]-4-piperidin-derivate, verafhren zu deren herstellung, pharmazeutische mixturen und intermediate zu deren herstellung
JP2000080081A (ja) 1998-06-24 2000-03-21 Dainippon Pharmaceut Co Ltd １―〔（１―置換―４―ピペリジニル）メチル〕―４―ピペリジン誘導体及びそれを含有する医薬組成物
JP2001122784A (ja) 1999-10-27 2001-05-08 Dainippon Pharmaceut Co Ltd １−［（１−置換−４−ピペリジニル）メチル］−４−ピペリジン誘導体からなる医薬

Also Published As

Publication number Publication date
SK50192004A3 (sk) 2005-04-01
ZA200409053B (en) 2005-07-12
MXPA04011332A (es) 2005-02-14
JP2004043453A (ja) 2004-02-12
TW200400186A (en) 2004-01-01
HUP0501016A2 (en) 2006-02-28
KR20040107520A (ko) 2004-12-20
EP1362857B1 (en) 2004-08-11
DK1362857T3 (da) 2004-12-20
DE60300021T2 (de) 2005-09-08
RU2004136853A (ru) 2005-06-27
PT1362857E (pt) 2004-11-30
CZ20041084A3 (cs) 2005-02-16
HK1060118A1 (en) 2004-07-30
US20030216433A1 (en) 2003-11-20
EP1362857A1 (en) 2003-11-19
IL165012A0 (en) 2005-12-18
TR200403020T2 (tr) 2005-05-23
CA2483368A1 (en) 2003-11-27
ES2227500T3 (es) 2005-04-01
ATE273304T1 (de) 2004-08-15
PL372724A1 (en) 2005-07-25
NO20045469L (no) 2005-02-16
CN1653063A (zh) 2005-08-10
AR040021A1 (es) 2005-03-09
WO2003097638A1 (en) 2003-11-27
US6696468B2 (en) 2004-02-24
DE60300021D1 (de) 2004-09-16
BR0309933A (pt) 2005-02-09
AU2003230245A1 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
JP3643107B2 (ja) （ｓ）−４−アミノ−５−クロロ−２−メトキシ−ｎ−［１−［１−（２−テトラヒドロフリルカルボニル）−４−ピペリジニルメチル］−４−ピペリジニル］ベンズアミド、その製造方法、それを含有する医薬組成物及び該化合物の中間体
TWI313264B (en) Triamide-substituted heterobicyclic compounds
CN1096459C (zh) (r)－5－溴－n－(1－乙基－4－甲基六氢－1h－1,4－二氮杂䓬－6－基)－2－甲氧基－6－甲胺基－3－吡啶羧酰胺,其制备方法及含有该化合物的医药组合物
JP2004277318A (ja) １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
KR101586507B1 (ko) 아미드 유도체 및 이를 함유하는 약학적 조성물
JP2004277319A (ja) １−（４−ピペリジニルメチル）ピペリジニルアミド誘導体およびそれを含有する医薬組成物
JP2005082508A (ja) ２−アルコキシ−６−アミノ−５−ハロゲノ−ｎ−（１−置換−４−ピペリジニル）ピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物
JP2005104896A (ja) ２−アルコキシ−６−アミノ−５−ハロゲノピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物
WO2006121104A1 (ja) ピペリジン環を有するインドール誘導体の結晶およびその製法
JP2001122784A (ja) １−［（１−置換−４−ピペリジニル）メチル］−４−ピペリジン誘導体からなる医薬
JP2005170933A (ja) （ｓ）−４−アミノ−５−クロロ−２−メトキシ−ｎ−［１−［１−（２−テトラヒドロフリルカルボニル）−４−ピペリジニルメチル］−４−ピペリジニル］ベンズアミドからなる医薬
JP2004277320A (ja) １，４−ジ置換ピペリジン誘導体およびそれを含有する医薬組成物
JPH10203987A (ja) （ｒ）−１−エチル−４−メチルヘキサヒドロ−１ｈ−１，４−ジアゼピン誘導体を有効成分とするモルヒネ様薬剤誘発嘔吐抑制剤
JP2990073B2 (ja) （ｒ）−１−エチル−４−メチルヘキサヒドロ−１ｈ−１，４−ジアゼピン誘導体及びそれを含有する医薬
JP5156806B2 (ja) アミド誘導体からなる医薬
JP2000319166A (ja) 腸溶製剤
JP2000080081A (ja) １―〔（１―置換―４―ピペリジニル）メチル〕―４―ピペリジン誘導体及びそれを含有する医薬組成物
HK1060118B (en) (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide for treating gastrointestinal motility disorders
JP3222051B2 (ja) ６−メトキシ−１ｈ−ベンゾトリアゾール−５−カルボキサミド誘導体
JPH09301972A (ja) Ｎ−（１−置換−アザシクロアルカン−３−イル）カルボキサミド誘導体及びそれを含有する医薬組成物
NO310770B1 (no) Estere av 3-hydroksy-piperidinmetanolderivater
JPWO2004024143A1 (ja) 医薬組成物
JP2010031063A (ja) 医薬組成物
JPWO1999055674A1 (ja) １−［（１−置換−４−ピペリジニル）メチル］−４−ピペリジン誘導体、その製造方法、それを含有する医薬組成物および該化合物の中間体
JPH08225571A (ja) ６−アルコキシ−１ｈ−ベンゾトリアゾール−５−カルボキサミド誘導体及びその中間体並びに該化合物を含有する医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040908

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20041115

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20050107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20050118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20050126

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees